Fig. 2

Upregulation of CREBH by A. muciniphila promotes intestinal barrier integrity. A Immunoblotting analysis of CREBH and loading control β-actin proteins in the colon tissues of WT mice treated with a dose of AKK or Veh every other day for 14 days. B mRNA expression of CREBH in the Veh or DSS treated colons determined by qRT-PCR. C Immunoblotting analysis of CREBH, CLDN2, CLDN3 and β-actin in the colons of mice treated with Veh or DSS. D Immunoblotting analysis of CREBH and β-actin in the colon tissues of the mice pre-treated with Veh or AKK followed by Veh or DSS treatment. E Immunoblotting analysis of CLDN2, OCLN and β-actin in the colon tissues of the WT and CREBH-KO mice. F qRT-PCR analysis of mRNAs of CLDN1, 3, 5, and 8, OCLN and ZO-1 in the colon tissues of WT or CREBH-KO mice treated with Veh or DSS. G FD4 gut permeability assay: two groups of DSS-treated WT and KO mice were subjected to a FD4 permeability assay as described in the "Methods". Plasma FD4 concentrations were determined and presented as means ± SD. H Plasma endotoxin (LPS) concentrations from the control WT/Veh/Veh, KO/Veh/DSS or KO/AKK/DSS treated mice determined as described in the "Methods". Results represent the means ± SD. The two-tailed Student’s t-test was used for statistical analyses of two-group comparisons. *P < 0.05 and **P < 0.01 versus controls